MedTrace Logo

Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers

NCT00832871 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-06-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if mifepristone prevents worsening of your cancer. Mifepristone is an antiprogesterone agent, a drug which blocks female hormones, that is commonly used for the termination of pregnancies. It has not been approved by the Food and Drug Administration for use in the treatment of cancer. It is unlicensed in the United States for your condition. However, previous work has indicated that mifepristone may be useful due to how it works. It is being made available for use in the United States for compassionate use through the Feminist Majority Foundation.

Conditions

Interventions

DRUG

Mifepristone

Mifepristone 200 mg will be administered orally

Sponsors & Collaborators

  • The Feminist Majority Foundation

    collaborator OTHER

  • New Mexico Cancer Research Alliance

    lead OTHER

Principal Investigators

  • Fa-Chyi Lee, M.D. · University of New Mexico Cancer Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00832871 on ClinicalTrials.gov